Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis

J Cyst Fibros. 2012 Dec;11(6):494-501. doi: 10.1016/j.jcf.2012.04.007. Epub 2012 May 12.


Background: Our objective was to confirm the measurement properties of the Treatment Satisfaction Questionnaire with Medication (TQSM) in patients with cystic fibrosis (CF) receiving inhaled antibiotics.

Methods: The TSQM was included in the EAGER study, a clinical trial comparing a nebulized and a dry powder device for inhaled tobramycin in a CF population with chronic Pseudomonas aeruginosa (Pa) lung infection, aged 6 years and above (N=553). Reliability and validity of the questionnaire were investigated using Cronbach's α and multitrait-multimethod approach.

Results: The TSQM demonstrated very good reliability and construct validity: all Cronbach's α were above 0.86 and all items met the convergent and discriminant validity criteria. In multivariate regressions, higher patient satisfaction and lower perceived impact of side-effects were associated with better treatment compliance.

Conclusions: The TSQM showed very good measurement properties that strongly support its use to assess satisfaction of patients with CF taking inhaled antibiotics.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / adverse effects
  • Child
  • Cystic Fibrosis / microbiology*
  • Female
  • Humans
  • Male
  • Medication Adherence
  • Nebulizers and Vaporizers
  • Patient Satisfaction*
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / microbiology
  • Pseudomonas Infections / drug therapy
  • Pseudomonas aeruginosa
  • Psychometrics / standards
  • Reproducibility of Results
  • Surveys and Questionnaires / standards*
  • Tobramycin / administration & dosage*
  • Tobramycin / adverse effects
  • Young Adult


  • Anti-Bacterial Agents
  • Tobramycin